The Internally Truncated LRP5 Receptor Presents a Therapeutic Target in Breast Cancer
2009

The Internally Truncated LRP5 Receptor as a Target in Breast Cancer

Sample size: 19 publication 10 minutes Evidence: moderate

Author Information

Author(s): Björklund Peyman, Svedlund Jessica, Olsson Anna-Karin, Åkerström Göran, Westin Gunnar

Primary Institution: Uppsala University

Hypothesis

Is the internally truncated LRP5 receptor involved in breast cancer progression?

Conclusion

The LRP5Δ receptor is implicated in breast cancer and may serve as a therapeutic target.

Supporting Evidence

  • LRP5Δ was expressed in 84% of analyzed breast tumors.
  • Inhibition of LRP5Δ led to reduced cell growth and increased apoptosis in breast cancer cells.
  • The study found that LRP5Δ is required for the accumulation of active β-catenin in breast cancer cells.

Takeaway

Scientists found a special version of a protein called LRP5 that helps breast cancer grow, and they think it could be a good target for new treatments.

Methodology

The study used reverse transcription PCR and Western blot analysis to assess LRP5Δ expression in breast tumors and MCF7 cells.

Potential Biases

Potential bias in sample selection and analysis methods.

Limitations

The study was limited to a specific number of breast cancer specimens and may not represent all breast cancer types.

Participant Demographics

The study analyzed breast cancer specimens from patients with varying cancer stages.

Statistical Information

P-Value

<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0004243

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication